ProQR Therapeutics (NASDAQ:PRQR) Downgraded to “Sell” Rating by StockNews.com

ProQR Therapeutics (NASDAQ:PRQR) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.

A number of other research analysts have also recently issued reports on the company. Raymond James upgraded ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $6.00 to $14.00 in a research report on Tuesday, October 29th. HC Wainwright lifted their price target on shares of ProQR Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, ProQR Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $7.13.

ProQR Therapeutics Price Performance

Shares of PRQR opened at $3.84 on Thursday. The firm has a 50 day simple moving average of $3.08 and a two-hundred day simple moving average of $2.29. ProQR Therapeutics has a one year low of $1.35 and a one year high of $4.62. The company has a market cap of $313.65 million, a P/E ratio of -12.00 and a beta of 0.26.

Institutional Trading of ProQR Therapeutics

A number of hedge funds have recently made changes to their positions in PRQR. OneDigital Investment Advisors LLC increased its stake in shares of ProQR Therapeutics by 37.0% in the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 15,550 shares during the period. BNP Paribas Financial Markets grew its holdings in ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 7,300 shares during the last quarter. Finally, Privium Fund Management B.V. increased its position in ProQR Therapeutics by 4.4% in the 2nd quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock valued at $9,208,000 after acquiring an additional 236,279 shares during the period. 32.65% of the stock is owned by institutional investors and hedge funds.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).